ERBB2 and breast carcinoma: Furthermore, the data from the ExteNET clinical trial confirmed that neratinib significantly improved invasive disease-free survival when given as a year extended adjuvant therapy after chemotherapy and trastuzumab-based adjuvant therapy in HER2-positive breast cancer [15, 16].